COVID-19 ACTION PLAN
Our top priority is the health and well-being of our employees, clinical trial participants, business and community partners.
Continuing Clinical Trials
We do not foresee an issue with the continued supply of investigational medicines for patients in our clinical trials at this time. We continue to monitor the evolving situation as we support clinical trial sites and patients participating in our trials. In some cases, study visits may be conducted by phone. For trials that require in-office/in-hospital testing, e.g., cardiopulmonary exercise testing (CPET), certain trial visits may be delayed until it is more feasible to conduct them. If you are a patient who is participating in one of our ongoing clinical trials, we ask you to please contact your clinical site directly for updates.
Engaging in Ongoing Discussions with Regulatory Authorities
We are continuing interactions with regulatory authorities. The FDA recently released a guidance document regarding the conduct of clinical trials that provides helpful information to sponsors of clinical trials.
Supporting our Workforce and our Community
In accordance with the California state government “shelter in place” order, our employees are working from home until further notice. As such, all business travel has been suspended. Cytokinetics will participate in upcoming medical and investor conferences virtually. During this time, we are doing all that we can to ensure that critical work required to bring our potential medicines to patients continues.
Overall Business Outlook
We are doing what we can to minimize potential business disruption during this very fluid situation and will remain nimble to further adjust accordingly. Again, our top priority remains the health and well-being of our employees and the patients we serve every day. We will continue to actively monitor the situation closely and will provide updates.